GNE-431

• Description:

  GNE-431 is a potent, selective and noncovalent “pan-BTK” inhibitor against C481R, T474I and T474Ms mutants. GNE-431 shows potency against wild-type BTK (IC50= 3.2 nM) and potency against C481S mutant (IC50= 2.5 nM) . GNE-431 is proming for rasearch of haematological disorders and autoimmune diseases[1][2].

• UNSPSC:

  12352005

• Target:

  Btk

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/gne-431.html

• Smiles:

  O=C1N (C2=NC=CC (C3=NN4C (C (NC5=NN6C (CN (C) CC6) =C5) =C3) =NC=C4) =C2CO) CCN7C1=CC8=C7CCCC8

• Molecular Formula:

  C30H32N10O2

• Molecular Weight:

  564.64

• References & Citations:

  [1]Tasso B, et al. The Development of BTK Inhibitors: A Five-Year Update. Molecules. 2021 Dec 6;26 (23) :7411.|[2]Brullo C, et al. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021 Jul 16;22 (14) :7641.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1433820-83-7